Literature DB >> 24876578

The Minimum Duration of Sensor Data From Which Glycemic Variability Can Be Consistently Assessed.

Orla M Neylon1, Peter A Baghurst2, Fergus J Cameron3.   

Abstract

Despite much discussion regarding the clinical relevance of glycemic variation (GV), little discourse has addressed the properties of the data set from which it is derived. We aimed to assess the minimum duration of data required using continuous glucose monitoring (CGM) that most closely approximates to a gold standard 90-day measure. Data from 20 children and adolescents with type 1 diabetes were examined. All participants had CGM data sets of 90 days duration, from which standard deviation (SD), coefficient of variation (CV), mean amplitude of glycemic action (MAGE), and continuous overlapping net glycemic action (CONGA1-8) were calculated for the overall period and then investigational periods of 2, 4, 6, 12, 18, 24, and 30 days. The percentage difference between each measure and the overall measure per time period was assessed. As the duration of the CGM data set increased, the percentage error continued to decrease, giving a metric approximating more closely toward the overall measure. Median SD and CV differed from the overall measure by <10% at 12 days duration. The frequency of interruptions to the CGM trace rendered MAGE and CONGA unreliable, hence SD and CV were reported. We suggest that data sets used to infer GV should be of a minimum duration of 12 days. MAGE and CONGA exhibit poor performance in the setting of frequent trace interruption.
© 2014 Diabetes Technology Society.

Entities:  

Keywords:  CONGA; MAGE; continuous glucose monitoring; glycemic variation; pediatric; standard deviation; type 1 diabetes

Year:  2014        PMID: 24876578      PMCID: PMC4455394          DOI: 10.1177/1932296813519011

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  22 in total

Review 1.  Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2009-06       Impact factor: 6.118

2.  Determination of the glycosylated hemoglobins (HB AI) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus.

Authors:  E C Abraham; T A Huff; N D Cope; J B Wilson; E D Bransome; T H Huisman
Journal:  Diabetes       Date:  1978-09       Impact factor: 9.461

3.  The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial.

Authors:  F J Service; P C O'Brien
Journal:  Diabetologia       Date:  2001-10       Impact factor: 10.122

Review 4.  For debate. Glucose variability and diabetes complication risk: we need to know the answer.

Authors:  E S Kilpatrick; A S Rigby; S L Atkin
Journal:  Diabet Med       Date:  2010-08       Impact factor: 4.359

5.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes.

Authors:  I M E Wentholt; W Kulik; R P J Michels; J B L Hoekstra; J H DeVries
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

6.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation.

Authors:  Lisa Quagliaro; Ludovica Piconi; Roberta Assaloni; Lucia Martinelli; Enrico Motz; Antonio Ceriello
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

7.  The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study.

Authors:  S O Oyibo; Y D M Prasad; N J Jackson; E B Jude; A J M Boulton
Journal:  Diabet Med       Date:  2002-10       Impact factor: 4.359

8.  Glycemic variability: should we and can we prevent it?

Authors:  Louis Monnier; Claude Colette
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

9.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation.

Authors:  Edmond A Ryan; Tami Shandro; Kristy Green; Breay W Paty; Peter A Senior; David Bigam; A M James Shapiro; Marie-Christine Vantyghem
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

10.  Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.

Authors:  Roy W Beck; Bruce Buckingham; Kellee Miller; Howard Wolpert; Dongyuan Xing; Jennifer M Block; H Peter Chase; Irl Hirsch; Craig Kollman; Lori Laffel; Jean M Lawrence; Kerry Milaszewski; Katrina J Ruedy; William V Tamborlane
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 19.112

View more
  7 in total

1.  Assessment of Glucose Control Metrics by Discriminant Ratio.

Authors:  Vanessa Moscardó; Pau Herrero; Monika Reddy; Nathan R Hill; Pantelis Georgiou; Nick Oliver
Journal:  Diabetes Technol Ther       Date:  2020-10       Impact factor: 6.118

2.  Impact of a Basal-Bolus Insulin Regimen on Metabolic Control and Risk of Hypoglycemia in Patients With Diabetes Undergoing Peritoneal Dialysis.

Authors:  Ana María Gómez; Santiago Vallejo; Freddy Ardila; Oscar M Muñoz; Álvaro J Ruiz; Mauricio Sanabria; Alfonso Bunch; Elly Morros; Laura Kattah; Maira García-Jaramillo; Fabián León-Vargas
Journal:  J Diabetes Sci Technol       Date:  2017-09-20

3.  Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus.

Authors:  Marc D Breton; Stephen D Patek; Dayu Lv; Elaine Schertz; Jessica Robic; Jennifer Pinnata; Laura Kollar; Charlotte Barnett; Christian Wakeman; Mary Oliveri; Chiara Fabris; Daniel Chernavvsky; Boris P Kovatchev; Stacey M Anderson
Journal:  Diabetes Technol Ther       Date:  2018-07-06       Impact factor: 6.118

Review 4.  Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

5.  A Simple Composite Metric for the Assessment of Glycemic Status from Continuous Glucose Monitoring Data: Implications for Clinical Practice and the Artificial Pancreas.

Authors:  Irl B Hirsch; Andrew K Balo; Kevin Sayer; Arturo Garcia; Bruce A Buckingham; Thomas A Peyser
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

6.  Feasibility and acceptability of ambulatory glucose profile in children with Type 1 diabetes mellitus: A pilot study.

Authors:  Sushma Rai; Anjana Hulse; Prasanna Kumar
Journal:  Indian J Endocrinol Metab       Date:  2016 Nov-Dec

7.  The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.

Authors:  Ignacio Conget; Javier Castaneda; Goran Petrovski; Bruno Guerci; Anne-Sophie Racault; Yves Reznik; Ohad Cohen; Sarah Runzis; Simona de Portu; Ronnie Aronson
Journal:  Diabetes Technol Ther       Date:  2015-08-04       Impact factor: 6.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.